Breaking News Instant updates and real-time market news.

RXII

RXi Pharmaceuticals

$0.71

-0.012 (-1.67%)

, OPK

OPKO Health

$9.19

-0.04 (-0.43%)

17:42
01/12/17
01/12
17:42
01/12/17
17:42

On The Fly: After Hours Movers

HIGHER: RXi Pharmaceuticals (RXII), up 17.7% after Opko Health (OPK) reported a 5.11% passive stake in the company... Pandora (P), up 7.2% after it said it expects to exceed its previously provided fourth quarter revenue and adjusted EBITDA guidance and said it plans to cut its U.S. employee base by roughly 7% by the end of the first quarter of 2017... Nivalis (NVLS), up 1.8% after it said it plans to cut its workforce by 25 employees, including president and chief executive officer Jon Congleton. LOWER: Two Harbors (TWO), down 1.7% after it announced an offering of $250M of convertible senior notes... WPX Energy (WPX), down 1.3% after it filed to sell 42M shares of common stock and agreed to acquire assets to increase its Permian operations in a transaction valued at $775M.

RXII

RXi Pharmaceuticals

$0.71

-0.012 (-1.67%)

OPK

OPKO Health

$9.19

-0.04 (-0.43%)

P

Pandora

$12.00

0.11 (0.93%)

NVLS

Changed to ALPN

$2.21

-0.06 (-2.64%)

TWO

Two Harbors

$8.81

-0.04 (-0.45%)

WPX

WPX Energy

$13.78

-0.19 (-1.36%)

  • 12

    Jan

  • 23

    Feb

  • 28

    Feb

RXII RXi Pharmaceuticals
$0.71

-0.012 (-1.67%)

06/07/16
HCWC
06/07/16
INITIATION
Target $3.5
HCWC
Buy
RXi Pharmaceuticals assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Carol Ann Werther assumed coverage of RXi Pharmaceuticals with a Buy rating and $3.50 price target.
OPK OPKO Health
$9.19

-0.04 (-0.43%)

12/30/16
STPT
12/30/16
NO CHANGE
Target $18
STPT
Buy
OPKO Health selloff an overreaction, says Standpoint Research
After speaking with the company's CEO Phillip Frost, Standpoint Research says today's selloff in the shares of OPKO Health is an overreaction. The stock is down 16% to $9.65. Standpoint expects today's bad news to be reversed in the next six to 12 weeks. The firm reiterates a Buy rating on the shares with an $18 price target.
01/03/17
BRRR
01/03/17
NO CHANGE
Target $15
BRRR
Outperform
Selling OPKO Friday likely a mistake, says Barrington
Investors who sold shares of OPKO Health on Friday's news likely made a mistake, Barrington analyst Michael Petusky tells investors in a research note. The analyst does not believe Pfizer (PFE) would have agreed to the language in the OPKO press release that cited "one or more outliers" if this were not a potentially game-changing issue. Petusky keeps an Outperform rating on shars of OPKO with a $15 price target.
10/07/16
JEFF
10/07/16
NO CHANGE
Target $10
JEFF
Hold
Palmetto no-coverage decision 'major setback' for OPKO, says Jefferies
Jefferies analyst Brandon Couillard views Palmetto's no-coverage decision yesterday for OPKO Health's 4Kscore prostate cancer test as a "major setback." Palmetto is a Medicare administrative contractor. The analyst views 4Kscore as a key near-term growth driver for OPKO and believes the company's local Medicare administrative contractor Novitas will likely follow suit. Without Medicare, 4K's commercial pathway from here is unclear, Couillard tells investors in a research note. He expects OPKO shares to trade lower on renewed reimbursement concerns. The analyst has a Hold rating on the name.
01/10/17
PIPR
01/10/17
NO CHANGE
PIPR
Overweight
Natera distribution pact termination a positive, says Piper Jaffray
Piper Jaffray analyst William Quirk said Natera's (NTRA) termination of a distribution agreement with Bio-Reference Laboratories, which has been acquired by OPKO Health (OPK), is a positive for Natera as the company has many payer contracts in place and has successfully transitioned a series of physicians to a direct model in the past. Natera will now directly market Panorama to clinicians as well as market Horizon to them, which Bio-Reference had not previously done, said Quirk, who keeps an Overweight rating on Natera shares.
P Pandora
$12.00

0.11 (0.93%)

01/03/17
BRRR
01/03/17
DOWNGRADE
BRRR
Market Perform
Townsquare Media downgraded on lagging growth at Barrington
Barrington analyst James Goss downgraded Townsquare Media (TSQ) to Market Perform saying the company's growth lags what he expects from Outperform-rated names. The analyst intratday also downgraded Pandora Media (P) to Market Perform.
01/03/17
BRRR
01/03/17
DOWNGRADE
BRRR
Market Perform
Pandora downgraded on valuaton at Barrington
Barrington analyst James Goss downgraded Pandora Media to Market Perform citing valuation with the shares close to his previous price target. The analyst also expects management's initiatives to take time to develop.
01/03/17
BRRR
01/03/17
DOWNGRADE
BRRR
Market Perform
Pandora downgraded to Market Perform from Outperform at Barrington
01/11/17
MACQ
01/11/17
NO CHANGE
Target $5
MACQ
Outperform
Sirius XM attractive with or without Pandora acquisition, says Macquarie
Macquarie analyst Amy Yong believes that Sirius XM (SIRI) shares are attractive whether or not the company were to pursue an acquisition of Pandora (P), but that such a deal could refresh the long-term story and rerate the shares. She estimates the purchase of Pandora, assuming a $15 per share offer, would dilute Sirius XM's 2017 free cash flow per share by about 3%, adding Sirius XM's balance sheet "could easily absorb an all-cash or mostly-cash deal." Meanwhile, Sirius and parent Liberty could strengthen Pandora's execution while the satellite-digital combination and the addition of Pandora's over 80M active users "could single-handedly resolve Sirius XM's digital strategy," argues Yong, who raised her price target on Sirius shares to $5 from $4.85 and maintains an Outperform rating on the stock.
NVLS Changed to ALPN
$2.21

-0.06 (-2.64%)

11/29/16
11/29/16
DOWNGRADE

On The Fly: Top five analyst downgrades
On The Fly: Top five analyst downgrades: 1. Wendy's (WEN) downgraded to Neutral from Buy at Goldman with analyst Karen Holthouse citing valuation with the stock up 23% over the past month. 2. SAIC (SAIC) downgraded to Neutral from Buy at Citi with analyst Jonathan Raviv citing the recent rally in the shares and some overhang from the pending contract transition. 3. BioMarin (BMRN), Johnson & Johnson (JNJ), and Vertex (VRTX) were downgraded to Equal Weight from Overweight at Barclays. 4. Nivalis Therapeutics (NVLS) downgraded to Market Perform Raymond James, to Hold from Buy at Stifel, to Market Perform from Outperform at Cowen, and to Neutral from Outperform at Baird. 5. U.S. Steel (X) downgraded to Hold from Buy at Argus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/29/16
COWN
11/29/16
DOWNGRADE
COWN
Market Perform
Nivalis Therapeutics downgraded to Market Perform at Cowen
As reported previously, Cowen analyst Phil Nadeau downgraded Nivalis Therapeutics to Market Perform from Outperform. The analyst said its proof-of-concept Phase 2 trial for cystic fibrosis demonstrated no benefits for lung function or sweat chloride, two established measures of activity. The drug was the company's primary asset, Nadeau noted.
11/29/16
STFL
11/29/16
DOWNGRADE
STFL
Hold
Nivalis Therapeutics downgraded on lack of drug efficacy at Stifel
As noted earlier, Stifel downgraded Nivalis to Hold from Buy. Analyst Thomas Shrader downgraded the stock after the company's cavosonstat for CF did not show meaningful efficacy in a Phase II trial. Target to $3.25 from $16.
11/29/16
11/29/16
DOWNGRADE
Target $3

Neutral
Nivalis Therapeutics downgraded to Neutral at Baird
As previously reported, Baird analyst Brian Skorney downgraded Nivalis Therapeutics to Neutral from Outperform following the clinical trial failure of its flagship proof-of-concept study of its drug for cystic fibrosis. Skorney lowered his price target to $3 from $29 on Nivalis Therapeutics shares. Nivalis shares have also been downgraded by at least three other firms this morning.
TWO Two Harbors
$8.81

-0.04 (-0.45%)

11/03/16
WELS
11/03/16
UPGRADE
WELS
Outperform
Two Harbors upgraded to Outperform from Market Perform at Wells Fargo
11/04/16
WELS
11/04/16
UPGRADE
WELS
Outperform
Two Harbors upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Joel Houck last night upgraded Two Harbors Investment to Outperform from Market Perform saying he sees a "strong case" for fundamental earnings growth following the company's Q3 results. The analyst raised his price target range for the shares to $9.00-$9.50 from $8.50-$9.00.
09/06/16
09/06/16
DOWNGRADE
Target $9

Market Perform
Two Harbors downgraded to Market Perform from Outperform at FBR Capital
FBR Capital analyst Jessica Levi-Ribner downgraded Two Harbors Investment to Market Perform saying the shares are fairly valued at current levels. The analyst raised her price target for the stock to $9 from $8.50.
01/15/16
WELS
01/15/16
DOWNGRADE
WELS
Market Perform
Two Harbors downgraded to Market Perform from Outperform at Wells Fargo
WPX WPX Energy
$13.78

-0.19 (-1.36%)

12/12/16
RHCO
12/12/16
NO CHANGE
RHCO
WPX Energy price target raised to $20 from $15 at SunTrust
SunTrust analyst Neal Dingmann says that upcoming increased drilling by WPX will enable the company to exploit higher commodity prices and improved efficiencies. The analyst raised his estimates for the company and keeps a Buy rating on the stock.
12/13/16
12/13/16
NO CHANGE

Baird sees Aramco IPO as reason for Saudis to follow through on cuts
Baird's energy research team, headed by Ethan Bellamy, Daniel Katzenberg, and Michael Gaiden, note Saudi Arabia is prepping the crude oil market for the floatation of the largest publicly traded company in history, Saudi Aramco, and they believe the Kingdom will follow through and balance the market in January as the "long-term payoff of that pricing exceeds a few quarters of production curtailment." Given that view, the firm recommends buying oil and oil-linked names and holding them through the deal, identifying Carrizo Oil & Gas (CRZO), WPX Energy (WPX) and Whiting Petroleum (WLL), Plains All American (PAA) and Plains GP Holdings (PAGP) as names to own based on their year-to-date correlations to oil.
11/28/16
DBAB
11/28/16
UPGRADE
Target $17
DBAB
Buy
WPX Energy upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Josh Silverstein upgraded WPX Energy to Buy citing valuation and the company's margin improvement. The analyst raised his price target for the shares to $17 from $15.
11/14/16
BMOC
11/14/16
UPGRADE
BMOC
Outperform
WPX Energy upgraded to Outperform from Market Perform at BMO Capital

TODAY'S FREE FLY STORIES

OAS

Oasis Petroleum

09:00
12/12/17
12/12
09:00
12/12/17
09:00
Syndicate
Oasis Petroleum 32M share Spot Secondary priced at $9.55 »

The deal range was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

PRSC

Providence Service

$58.26

0.08 (0.14%)

09:00
12/12/17
12/12
09:00
12/12/17
09:00
Syndicate
Providence Service 320K share Block Trade priced at $56.75 »

Jefferies acted as sole…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

DXTR

Dextera Surgical

$0.14

-0.003 (-2.14%)

09:00
12/12/17
12/12
09:00
12/12/17
09:00
Hot Stocks
Breaking Hot Stocks news story on Dextera Surgical »

Dextera Surgical trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GKOS

Glaukos

$24.85

-1.11 (-4.28%)

08:59
12/12/17
12/12
08:59
12/12/17
08:59
Recommendations
Glaukos analyst commentary  »

Reimbursement remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLYC

GlycoMimetics

$14.32

-0.65 (-4.34%)

08:57
12/12/17
12/12
08:57
12/12/17
08:57
Recommendations
GlycoMimetics analyst commentary  »

GlycoMimetics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

08:56
12/12/17
12/12
08:56
12/12/17
08:56
General news
Redbook Store Sales data reported »

Week of 12/9 Redbook…

BAC

Bank of America

$28.94

-0.11 (-0.38%)

, T

AT&T

$36.90

0.17 (0.46%)

08:55
12/12/17
12/12
08:55
12/12/17
08:55
Options
Notable open interest changes for December 12th »

Monday's total…

BAC

Bank of America

$28.94

-0.11 (-0.38%)

T

AT&T

$36.90

0.17 (0.46%)

AAPL

Apple

$172.67

3.3 (1.95%)

MU

Micron

$43.01

-0.2 (-0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

  • 09

    Jan

08:55
12/12/17
12/12
08:55
12/12/17
08:55
General news
Treasury Action: yields extended their rise »

Treasury Action: yields…

HI

Hillenbrand

$45.10

-0.45 (-0.99%)

08:55
12/12/17
12/12
08:55
12/12/17
08:55
Conference/Events
Hillenbrand to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

ARGX

Argenx

$54.47

24.02 (78.88%)

08:54
12/12/17
12/12
08:54
12/12/17
08:54
Technical Analysis
Technical View: Argenx falls after filing to sell $150M in ADSs »

In premarket trading the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

URBN

Urban Outfitters

$32.27

-0.82 (-2.48%)

08:53
12/12/17
12/12
08:53
12/12/17
08:53
Recommendations
Urban Outfitters analyst commentary  »

Urban Outfitters price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

H

Hyatt

$71.90

-0.39 (-0.54%)

08:53
12/12/17
12/12
08:53
12/12/17
08:53
Syndicate
Hyatt 2.7M share Block Trade priced at $71.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 12

    Dec

AGN

Allergan

$172.76

4.96 (2.96%)

08:53
12/12/17
12/12
08:53
12/12/17
08:53
Hot Stocks
Allergan receives FDA clearance for CoolSculpting treatment »

Allergan announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

GRMN

Garmin

$61.96

-0.31 (-0.50%)

08:52
12/12/17
12/12
08:52
12/12/17
08:52
Recommendations
Garmin analyst commentary  »

Garmin price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:50
12/12/17
12/12
08:50
12/12/17
08:50
General news
FX Action: The dollar »

FX Action: The dollar…

ESL

Esterline

$70.80

0.95 (1.36%)

08:49
12/12/17
12/12
08:49
12/12/17
08:49
Recommendations
Esterline analyst commentary  »

Esterline price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$283.16

-2.74 (-0.96%)

08:48
12/12/17
12/12
08:48
12/12/17
08:48
Recommendations
Boeing analyst commentary  »

Boeing price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RYCEY

Rolls-Royce

$11.08

-0.145 (-1.29%)

08:46
12/12/17
12/12
08:46
12/12/17
08:46
Hot Stocks
Rolls-Royce launches R2 Data Labs to accelerate data innovation »

Rolls-Royce has launched…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAOI

Applied Optoelectronics

$40.52

1.83 (4.73%)

, ROKU

Roku

$47.98

3.19 (7.12%)

08:45
12/12/17
12/12
08:45
12/12/17
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

AAOI

Applied Optoelectronics

$40.52

1.83 (4.73%)

ROKU

Roku

$47.98

3.19 (7.12%)

RSX

Market Vectors Russia ETF

$22.01

0.44 (2.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIBB

Hibbett Sports

$20.20

0.05 (0.25%)

08:43
12/12/17
12/12
08:43
12/12/17
08:43
Technical Analysis
Technical View: Hibbett Sports moves higher on light volume »

In pre-market trading the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$112.37

-0.23 (-0.20%)

08:42
12/12/17
12/12
08:42
12/12/17
08:42
Periodicals
Visa innovation chief had history of employee affairs before firing, Recode says »

Former Visa executive Jim…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

ATRO

Astronics

$42.06

-1.19 (-2.75%)

08:40
12/12/17
12/12
08:40
12/12/17
08:40
Recommendations
Astronics analyst commentary  »

Astronics price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:40
12/12/17
12/12
08:40
12/12/17
08:40
General news
U.S. headline PPI rose 0.4% in November with the core rate up 0.3% »

U.S. headline PPI rose…

08:40
12/12/17
12/12
08:40
12/12/17
08:40
General news
Breaking General news story  »

Week of 12/9 Redbook to…

PEGI

Pattern Energy

08:38
12/12/17
12/12
08:38
12/12/17
08:38
Downgrade
Pattern Energy rating change  »

Pattern Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.